ARCHIVES

Phase II Study Cohort Fails To Overcome Erlotinib Resistance

This article is from The Cancer Letter archive.

Vol. 36 No. 4 | April 26, 2013

Download PDF Visit The Full Archive

Related Articles

Phase III Tumor Treating Fields Trial Halted Following Positive Results in Interim Analysis

November 28, 2014

UHC Expands Risk Models To Include 25 Cancer Variables

February 24, 2012

Avastin Improves PFS Compared To Chemo Alone

January 29, 2010

PV-10 Produces 51 Percent Response Rate in Phase II Trial

October 26, 2012

Wichita CCOP Stopped Accrual For Two Months, PI Says.

May 12, 2006

NCI Objects To Fisher As Scientific Director Of NSABP, Threatens To Cut Off Funding

May 6, 1994